ProMIS Neurosciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ProMIS Neurosciences, Inc. (PMN) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income2.78-13.21-18.06-9.79-4.44
Depreciation & Amortization0.000.020.250.050.01
Stock Based Compensation0.830.270.490.520.21
Change in Working Capital-11.732.945.40-1.560.69
Change in Accounts Receivable0.000.000.000.000.03
Change in Accounts Payable-6.114.962.68-0.030.07
Change in Other Working Capital-5.62-2.022.73-1.530.59
Other Operating Activities-19.06-0.87-3.631.180.12
Net Cash from Operating Activities-27.18-10.84-17.03-9.31-3.42
Investing Activities
Capital Expenditures0.000.000.00-0.01-0.09
Acquisitions0.000.000.000.000.00
Purchases of Investments0.000.00-0.030.000.00
Sales/Maturities of Investments0.030.030.030.030.00
Net Cash from Investing Activities0.000.000.000.09-0.09
Financing Activities
Common Stock Issued27.8817.754.9715.873.01
Common Stock Repurchased0.000.000.00-1.640.00
Other Financing Activities0.030.001.522.740.00
Net Cash from Financing Activities27.8817.756.4925.523.01
Summary
Effect of Forex Changes on Cash0.00-0.18-0.53-0.180.00
Net Change in Cash0.696.72-10.5416.14-0.50
Cash at Beginning of Period12.605.8816.820.810.00
Cash at End of Period13.2912.605.7516.940.00
Free Cash Flow-27.18-10.84-17.04-9.31-3.50
Supplemental Disclosures
Interest Paid0.080.200.090.000.00